sutthirat sutthisumdang
RBC has upgraded MannKind (NASDAQ:MNKD) to outperform from sector perform, citing the company’s Tyvaso DPI royalty revenue opportunity and orphan lung pipeline.
The investment bank estimates the company could get up to $200M per year in royalties for idiopathic pulmonary fibrosis